Pancrelipase

(Creon®)

Pancrelipase

Latest News

loading GIF

Drug updated on 4/17/2024

Dosage FormCapsule (oral; lipase/protease/amylase [3,000 USP/9,500 USP/15,000 USP], [6,000 USP/19,000 USP/30,000 USP], [120,000 USP/38,000 USP/60, 000 USP], [24,000 USP, 76,000 USP, 120,000 USP], [36,000 USP, 114,000 USP, 180,000 USP])
Drug ClassDigestive enzymes
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Pancrelipase (Creon) is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.
  • The information was derived from a single study which is a systematic review/meta-analysis.
  • In terms of effectiveness, Creon improves PEI-related malabsorption and supports weight maintenance across several patient groups including those with cystic fibrosis, chronic pancreatitis, pancreatic cancer, and post-surgical states.
  • For patients suffering from chronic pancreatitis specifically, Creon also alleviates PEI-related symptoms.
  • When compared to general treatment strategies for exocrine pancreatic insufficiency (PEI), Creon demonstrates superior safety and efficacy profiles according to the reviewed study.
  • The proven benefits of Creon in various population types and subgroups are highlighted.

Product Monograph / Prescribing Information

Document TitleYearSource
Creon (pancrelipase) Prescribing Information.2024AbbVie Inc. North Chicago, IL

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
Evidence-based clinical practice guidelines for chronic pancreatitis 2021.2022Journal of Gastroenterology